» Articles » PMID: 36157498

Chaperone-assisted E3 Ligase CHIP: A Double Agent in Cancer

Overview
Journal Genes Dis
Date 2022 Sep 26
PMID 36157498
Authors
Affiliations
Soon will be listed here.
Abstract

The carboxy-terminus of Hsp70-interacting protein (CHIP) is a ubiquitin ligase and co-chaperone belonging to Ubox family that plays a crucial role in the maintenance of cellular homeostasis by switching the equilibrium of the folding-refolding mechanism towards the proteasomal or lysosomal degradation pathway. It links molecular chaperones . HSC70, HSP70 and HSP90 with ubiquitin proteasome system (UPS), acting as a quality control system. CHIP contains charged domain in between N-terminal tetratricopeptide repeat (TPR) and C-terminal Ubox domain. TPR domain interacts with the aberrant client proteins chaperones while Ubox domain facilitates the ubiquitin transfer to the client proteins for ubiquitination. Thus, CHIP is a classic molecule that executes ubiquitination for degradation of client proteins. Further, CHIP has been found to be indulged in cellular differentiation, proliferation, metastasis and tumorigenesis. Additionally, CHIP can play its dual role as a tumor suppressor as well as an oncogene in numerous malignancies, thus acting as a double agent. Here, in this review, we have reported almost all substrates of CHIP established till date and classified them according to the hallmarks of cancer. In addition, we discussed about its architectural alignment, tissue specific expression, sub-cellular localization, folding-refolding mechanisms of client proteins, E4 ligase activity, normal physiological roles, as well as involvement in various diseases and tumor biology. Further, we aim to discuss its importance in HSP90 inhibitors mediated cancer therapy. Thus, this report concludes that CHIP may be a promising and worthy drug target towards pharmaceutical industry for drug development.

Citing Articles

Key roles of ubiquitination in regulating critical regulators of cancer stem cell functionality.

Guo Q, Qin H, Chen Z, Zhang W, Zheng L, Qin T Genes Dis. 2025; 12(3):101311.

PMID: 40034124 PMC: 11875185. DOI: 10.1016/j.gendis.2024.101311.


E3 ubiquitin ligase CHIP facilitates cAMP and cGMP signalling cross-talk by polyubiquitinating PDE9A.

Hao X, Hu Z, Li M, Zhang S, Tang M, Hao C EMBO J. 2025; 44(4):1249-1273.

PMID: 39806097 PMC: 11833080. DOI: 10.1038/s44318-024-00351-7.


Unveiling the HSF1 Interaction Network: Key Regulators of Its Function in Cancer.

Vladimirova S, Kokoreva N, Guzhova I, Alhasan B, Margulis B, Nikotina A Cancers (Basel). 2024; 16(23).

PMID: 39682216 PMC: 11640653. DOI: 10.3390/cancers16234030.


Chaperone-mediated autophagy modulates Snail protein stability: implications for breast cancer metastasis.

Ryu K, Lee K, Park S, Kim T, Hong K, Kim H Mol Cancer. 2024; 23(1):227.

PMID: 39390584 PMC: 11468019. DOI: 10.1186/s12943-024-02138-0.


E3 Ubiquitin Ligase CHIP Inhibits Haemocyte Proliferation and Differentiation via the Ubiquitination of Runx in the Pacific Oyster.

Dong M, Song Y, Wang W, Song X, Wu W, Wang L Cells. 2024; 13(18.

PMID: 39329719 PMC: 11430624. DOI: 10.3390/cells13181535.


References
1.
Wu H, Yao S, Zhang S, Wang J, Guo P, Li X . Elevated expression of Erbin destabilizes ERα protein and promotes tumorigenesis in hepatocellular carcinoma. J Hepatol. 2017; 66(6):1193-1204. DOI: 10.1016/j.jhep.2017.01.030. View

2.
Ding X, Goldberg M . Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP. PLoS One. 2009; 4(6):e5949. PMC: 2694275. DOI: 10.1371/journal.pone.0005949. View

3.
Kanack A, Newsom O, Scaglione K . Most mutations that cause spinocerebellar ataxia autosomal recessive type 16 (SCAR16) destabilize the protein quality-control E3 ligase CHIP. J Biol Chem. 2018; 293(8):2735-2743. PMC: 5827432. DOI: 10.1074/jbc.RA117.000477. View

4.
Wang X, Cao W, Zhang J, Yan M, Xu Q, Wu X . A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination. EMBO J. 2017; 36(9):1243-1260. PMC: 5412902. DOI: 10.15252/embj.201694058. View

5.
Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou A . Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013; 19(17):4824-31. PMC: 3935614. DOI: 10.1158/1078-0432.CCR-13-0477. View